Horizon Therapeutics Stock Price, News & Analysis (NASDAQ:HPTX)

$45.99 0.00 (0.00 %)
(As of 12/15/2017 04:59 AM ET)
Previous Close$45.99
Today's RangeN/A
52-Week Range$20.23 - $46.96
VolumeN/A
Average Volume786,899 shs
Market Capitalization$964.29 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics logoHorizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

Receive HPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HPTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorBiopharmaceuticals
SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.03)
Net IncomeN/A
Net Margins23.13%
Return on Equity21.30%
Return on Assets15.42%

Miscellaneous

EmployeesN/A
Outstanding Shares20,980,000

Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics Inc (NASDAQ:HPTX) announced its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to analysts' expectations of $24.60 million. Horizon Therapeutics had a net margin of 23.13% and a return on equity of 21.30%. The company's quarterly revenue was up 65.6% compared to the same quarter last year. View Horizon Therapeutics' Earnings History.

Who are some of Horizon Therapeutics' key competitors?

How do I buy Horizon Therapeutics stock?

Shares of Horizon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Horizon Therapeutics' stock price today?

One share of Horizon Therapeutics stock can currently be purchased for approximately $45.99.

How big of a company is Horizon Therapeutics?

Horizon Therapeutics has a market capitalization of $964.29 million.

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.


MarketBeat Community Rating for Horizon Therapeutics (HPTX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Horizon Therapeutics (NASDAQ:HPTX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Horizon Therapeutics (NASDAQ:HPTX) Earnings History and Estimates Chart

Earnings by Quarter for Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics (NASDAQ HPTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2015Q414($0.20)$0.47$24.60 million$30.80 millionViewN/AView Earnings Details
8/7/2014Q2($0.18)$0.89$22.00 million$37.10 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.17)($0.22)$2.17 million$7.30 millionViewN/AView Earnings Details
2/25/2013Q412($0.38)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Horizon Therapeutics (NASDAQ:HPTX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Horizon Therapeutics (NASDAQ:HPTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Horizon Therapeutics (NASDAQ HPTX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Horizon Therapeutics (NASDAQ:HPTX)

Horizon Therapeutics (NASDAQ HPTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/17/2015Christine A NashSVPSell10,000$37.56$375,600.00View SEC Filing  
3/10/2015Christine A NashSVPSell9,900$29.63$293,337.00View SEC Filing  
1/20/2015Christine A NashSVPSell5,000$24.82$124,100.00View SEC Filing  
6/6/2014Scott D SandellMajor ShareholderSell1,430$5.54$7,922.20View SEC Filing  
3/4/2014James HealyDirectorSell23,625$30.02$709,222.50View SEC Filing  
1/14/2014Christine NashSVPSell10,000$24.09$240,900.00View SEC Filing  
9/20/2013Highland Management Partners Vmajor shareholderSell5,754$25.84$148,683.36View SEC Filing  
9/18/2013Highland Management Partners Vmajor shareholderSell15,544$26.00$404,144.00View SEC Filing  
9/16/2013Highland Management Partners Vmajor shareholderSell8,300$26.29$218,207.00View SEC Filing  
9/11/2013Highland Management Partners VMajor ShareholderSell34,573$26.56$918,258.88View SEC Filing  
9/9/2013Highland Management Partners VMajor ShareholderSell18,048$26.06$470,330.88View SEC Filing  
8/5/2013Highland Management Partners Vmajor shareholderSell25,000$25.48$637,000.00View SEC Filing  
8/2/2013Highland Management Partners VMajor ShareholderSell47,245$25.35$1,197,660.75View SEC Filing  
5/30/2013Bay City Capital LlcMajor ShareholderSell17,366$21.06$365,727.96View SEC Filing  
5/20/2013Bay City Capital LlcMajor ShareholderSell131,455$22.68$2,981,399.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Horizon Therapeutics (NASDAQ HPTX) News Headlines

Source:

SEC Filings

Horizon Therapeutics (NASDAQ:HPTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Horizon Therapeutics (NASDAQ:HPTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Horizon Therapeutics (NASDAQ HPTX) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.